Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The colonic epithelial tight junction and mucin complexes represent the integrated physical and chemical defense system of the large intestine (Groschwitz & Hogan, 2009). Tight junctions (TJs) are specialized intercellular protein networks composed of transmembrane proteins like claudins and occludin, which are anchored by cytosolic scaffold proteins such as zonula occludens-1 (ZO-1) to regulate paracellular permeability (Zihni et al., 2016). Complementing this, the mucin complex, dominated by the gel-forming glycoprotein MUC2, forms a dense, two-layered mucus blanket that segregates the luminal microbiota from the underlying epithelium (Johansson et al., 2011). In pathological states like ulcerative colitis and Crohn's disease, the degradation of the mucus layer and the disassembly of TJs lead to increased intestinal permeability, allowing the translocation of pathogens and pro-inflammatory antigens (Michielan & D'Incà, 2015). Therapeutic interventions aim to reinforce this barrier, with agents like larazotide acting as zonulin antagonists to stabilize TJs, and others like lubiprostone promoting mucosal repair and secretion (Gopalakrishnan et al., 2012). Maintaining the integrity of these complexes is crucial for preventing chronic immune activation and systemic inflammation.
Restoration of the intestinal physical barrier through the modulation of tight junction proteins (e.g., claudins, occludin) and the stimulation of goblet cells to produce and secrete mucins (primarily MUC2) to prevent antigen translocation.
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Colonic epithelial mucosal barrier.